CRISPR Therapeutics AG - Common Shares — Quarterly Cash Flow (NASDAQ:CRSP) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 2.17 B2.03 B2.25 B2.27 B2.73 B2.65 B Total liabilities 336.94 M318.59 M329.33 M343.43 M911.26 M904.22 M Total equity 1.83 B1.71 B1.92 B1.92 B1.81 B1.75 B Total liabilities & shareholders' equities 2.17 B2.03 B2.25 B2.27 B2.73 B2.65 B Total debt —————— Net debt ——————

News

Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?

Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial Gains - Pfizer (NYSE:PFE), Mode

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2026 Update (BATS:ARKK)

Prime Medicine: An Initial Prognosis (NASDAQ:PRME)

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

ZTS Set to Report Q2 Earnings: Here's What Investors Should Expect

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline